Pegging the Value of Gene Discovery
Executive SummaryAbout a dozen major alliances have been formed over the past 18 months involving commercial rights to novel genes and gene sequences. The upfront commitment of equity and research dollars continues to be impressive, but the value of each deal more often falls in line with the needs of the individual customers. For gene discovery companies, the next hurdle is how to sustain the value of their technologies as genomic information becomes more broadly available.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.